Frontlight ResearchEarly access
Not yet taking people in SpainPhase 4
Gadopiclenol versus gadobutrol contrast dye for MRI scans of Crohn's disease perianal fistula
Compares two MRI contrast dyes for spotting perianal fistulas in adults with Crohn's disease.
Key facts
- Who runs it
- Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
- Where
- Barcelona, SpainSee the site
- Trial code
- Registry title
- Phase IV, single-center, randomized, crossover clinical trial to validate the use of gadopiclenol versus gadobutrol in the evaluation of magnetic resonance imaging (MRI) diagnosis of perianal fistula associated with Crohn's disease
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 30 people, planned
- Started
- 1 Dec 2025
- Expected to end
- 1 Oct 2027
- Type of study
- Interventional
- Record updated
- 18 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Crohn's disease who also have a perianal fistula (a tunnel near the anus) caused by it. It compares two MRI contrast agents.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Crohn's disease with perianal disease caused by it
Main reasons for not taking part
- Younger than 18 years
- Pregnant or breastfeeding
- Kidney failure (GFR below 30 ml/min in lab results up to 6 months old)
- Past allergic reaction to gadolinium contrast media
- Crohn's disease without perianal disease
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients of legal age with Crohn's disease and perianal disease attributable to their condition
- Subjects with onset of Crohn's disease with perianal disease
- Sign informed consent
Who cannot take part
- History of hypersensitivity reaction to gadolinium-containing contrast media
- Patients with Crohn's disease without perianal disease
- Renal failure (GFR ˂30 ml/min in recent laboratory values up to 6 months old)
- Age ˂18 years
- Pregnancy and/or breastfeeding
Where in Spain
- Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
About the trial
What the trial wants to find out
To validate the use of 0.05 mmol/kg of Gadopiclenol in the detection and monitoring of perianal fistulas by magnetic resonance imaging studies.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Phase IV, single-center, randomized, crossover clinical trial to validate the use of gadopiclenol versus gadobutrol in the evaluation of magnetic resonance imaging (MRI) diagnosis of perianal fistula associated with Crohn's disease
- Plain-language title
- Gadopiclenol versus gadobutrol contrast dye for MRI scans of Crohn's disease perianal fistulaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 18 December 2025